Clinical trials: Central Blood Pressure
Essential Hypertension
Comparing Safety and Efficacy of Amlodipine Verses S Amlodipine in Patients With Essential Hypertension
As a third-generation dihydropyridine calcium channel blocker (CCB), Amlodipine is mainly used in a single therapy or combined therapy for hypertension or angina.
- Trial name
- NCT04554303
- Testing
- S-amlodipine 2.5mg, Amlodipine 5mg
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Hypertension, Hypercholesterolemia
Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin
This study will assess and compare the efficacy and safety of valsartan and the combination of valsartan and simvastatin in patients with high blood pressure and high cholesterol.
- Conditions
- Hypertension, Hypercholesterolemia, Dyslipidemia
- Trial name
- NCT00385931
- Testing
- Valsartan and simvastatin
- Where
- United States
- Volunteers
- 412 people
- Sponsor
- Novartis
Hypertension
Retrospective Survey for Patients With Hypertension and Diabetes Mellitus
This study will address the treatment rate and control rate of hypertension, treatment pattern and factors to affect blood pressure control by examining (retrospective) medical records of hypertension patients having Type 2…
- Trial name
- CRYSTAL (NCT00681278)
- Where
- 13 sites in South Korea
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
Hypertension
A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension
This study assessed the blood pressure effect, safety and tolerability of LCI699 compared to placebo and eplerenone in participants with resistant hypertension.
- Trial name
- NCT00817635
- Testing
- LCI699, Eplerenone
- Where
- 38 sites in United States, Iceland
- Volunteers
- 155 people
- Sponsor
- Novartis
Essential Hypertension
Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
This study assessed the efficacy and safety of the valsartan/amlodipine 160/5 mg single-pill combination in patients with uncomplicated essential hypertension not adequately controlled (MSDBP ≥90 mmHg and <110 mmHg) on valsartan…
- Trial name
- NCT01001572
- Testing
- Valsartan/amlodipine 160/5 mg, Valsartan 160 mg
- Volunteers
- 932 people
- Sponsor
- Novartis
Hypertension
Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension
The purpose of this study is to evaluate the blood pressure lowering effects of a valsartan/amlodipine combination treatment and amlodipine monotherapy for the treatment of Black stage II hypertensive patients (MSSBP ≥ 160 mmHg).
- Trial name
- NCT00353912
- Testing
- valsartan + amlodipine
- Where
- United States
- Volunteers
- 571 people
- Sponsor
- Novartis
Chronic Kidney Disease, Hypertension
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), a progressive decrease in the kidneys' ability to work properly.
- Trial name
- NCT05491642
- Testing
- BAY3283142
- Where
- 4 sites in Bulgaria, Germany
- Volunteers
- 56 people
- Sponsor
- Bayer
Blood Pressure, Hypertension
Pivotal Clinical Trial to Evaluate the Blood Pressure Accuracy of 'CART-I Plus'
The goal of this clinical trial is to evaluate how accurately the CART-I plus developed by Sky Labs can measure blood pressure. The primary endpoint of this clinical trial is accuracy (mmHg) of 'CART-I plus' which is obtained by…
- Conditions
- Blood Pressure, Hypertension, Hypotension
- Trial name
- NCT05725148
- Testing
- CART-I plus
- Where
- South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sky Labs
Hypertension
Fimasartan Optimal Reduction Targeting Elevated Blood Pressure: the FORTE Study
The purpose of this study is to evaluate the effect of home blood pressure monitoring on controlling blood pressure and correlation between home blood pressure and clinic blood pressure in hypertensive patients receiving two or…
- Trial name
- NCT03254914
- Testing
- Home Blood Pressure
- Where
- South Korea
- Volunteers
- 3,554 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension, Stroke
Diurnal Variation in Hypertensive Stroke Patients
This study was conducted to evaluate and compare the effectiveness of Amodipin® (amlodipine camsylate) with that of Cozaar® (losartan potassium) in hypertensive patients with an acute ischemic stroke by measuring their 24-hour…
- Trial name
- NCT01830517
- Testing
- Amlodipine, Losartan
- Where
- South Korea
- Volunteers
- 84 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension
The purpose of this study is to evaluate the effect of ALN-AGT01 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of ALN-AGT01.
- Trial name
- KARDIA-1 (NCT04936035)
- Testing
- ALN-AGT01
- Where
- 75 sites in United States, Canada and 3 more
- Volunteers
- 394 people
- Sponsor
- Alnylam Pharmaceuticals
Hypotension
Hypotension Prediction Index Study (HPI Study)
A prospective, single-arm, open-label, multicenter post-approval study to determine whether the use of the Acumen HPI Software to guide intraoperative hemodynamic management in non-cardiac surgery reduces the duration of…
- Trial name
- NCT03805217
- Testing
- EV1000A Clinical Platform with Acumen Hypotension Prediction Index Feature Software
- Where
- 11 sites in United States
- Volunteers
- 485 people
- Sponsor
- Edwards Lifesciences
Symptomatic Neurogenic Orthostatic Hypotension
Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3, multi-center, open-label study to evaluate the safety and tolerability of ampreloxetine in subjects with primary autonomic failures (MSA, PD, and PAF) and symptomatic nOH over 182 weeks.
- Trial name
- OAK (NCT04095793)
- Testing
- ampreloxetine
- Where
- 55 sites in United States, Australia and 16 more
- Volunteers
- 110 people
- Sponsor
- Theravance Biopharma
Type 2 Diabetes Mellitus
Empagliflozin and Sympathetic Nerve Traffic
In this study the effects of the Inhibition of the Sodium-Glucose Linked Transporter 2 in the kidney with empagliflozin compared to hydrochlorothiazide on blood pressure and on central sympathic nervous activity will be examined.
- Trial name
- NCT03254849
- Testing
- Empagliflozin, Hydrochlorothiazide 25 mg
- Where
- Germany
- Volunteers
- 75 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Hyperlipidemias, Hypertension
Study to Evaluate the Effect of Improving Systolic BP and LDL-C Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab
The purpose of this study is to evaluate the effectiveness of Olostar Tablet on blood pressure and lipid profiles, obtain safety-related information for subgroups that failed to participate in the clinical trials, and to evaluate…
- Trial name
- NCT05411887
- Testing
- Rosuvastatin, Olmesartan Medoxomil
- Where
- South Korea
- Volunteers
- 2,845 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Essential Hypertension
Evaluation of Stendo Pulsating Suit on Microcirculation and Central Blood Pressure in Essential Hypertension Patients
The action of one Stendo pulsating suit session will be evaluated on 24 patients referred to the hypertension consultations for essential hypertension treated but not stabilized.
- Trial name
- NCT02277821
- Testing
- Stendo pulsating suit System
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Stendo
Hypertension
A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension
This study determined the maximum dose of LCI6999 with respect to effect on the ACTH-stimulated cortisol response in participants with hypertension.
- Trial name
- NCT00817414
- Testing
- LCI699
- Where
- 11 sites in United States, Iceland
- Volunteers
- 63 people
- Sponsor
- Novartis
Hypertension, Ischemic Stroke
Fimasartan Blood Pressure Lowering After Acute Stroke
This study evaluates the effectiveness of fimasartan-based antihypertensive treatment and prognosis in post-acute phase of ischemic stroke or transient ischemic attack patients.
- Conditions
- Hypertension, Ischemic Stroke, Transient Ischemic Attack
- Trial name
- FABULOUS (NCT03231293)
- Where
- 27 sites in South Korea
- Volunteers
- 1,035 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension
The purpose of this study is to access the efficacy and safety of LCZ696 compared to olmesartan in elderly Asian patients for the treatment of hypertension.
- Trial name
- NCT01615198
- Testing
- Olmesartan, LCZ696
- Where
- 79 sites in China, Hong Kong and 5 more
- Volunteers
- 588 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
AVE7688 in Patients With Mild to Moderate Blood Pressure
The primary objective is to assess the antihypertensive efficacy of 4 different AVE 7688 doses on the change from baseline in trough diastolic blood pressure at the end of week 12.
- Trial name
- RAVEL-1 (NCT00284128)
- Testing
- AVE7688, Losartan-potassium
- Where
- 21 sites in United States, Argentina and 19 more
- Volunteers
- 1,940 people
- Sponsor
- Sanofi